115 - Bottle of Lies, Generic Drugs Quality, Ranbaxy, Audits, and Inspiring Quality Pros with NYT Best-Selling Author, Katherine Eban

On this episode, I was joined by Katherine Eban, the New York Times best-selling author of "Bottle of Lies". In this episode, Katherine dives deep into her decade-long investigation into the quality issues prevalent in generic drug manufacturing overseas. Eban highlights the need for improving transparency in the pharmaceutical industry. She shares some inspiring stories of dedicated professionals in the industry who strive to ensure patients receive quality. Eban also discusses her findings on fraudulent practices in manufacturing plants and the role of quality data in drug production. The episode sheds light on the importance of understanding the manufacturing process behind generic drugs and critical quality control issues needing urgent attention. Time-Stamps: 02:12 The Start of the Investigation into Generic Drug Quality 08:59 The Impact of Quality Issues on Global Health 12:54 Understanding the FDA's Role in Drug Quality Control 16:55 The Struggle to Maintain Quality in the Pharmaceutical Industry 18:39 The Ranbaxy Story 27:45 Peter Baker 30:19 Quality Stories 33:27 Conclusion and Final Thoughts Link to Katherine's Book: Bottle of Lies: The Inside Story of the Generic Drug Boom, is a New York Times bestseller and one of the New York Times’ 100 Notable Books of 2019.